Publications by authors named "Mikalai Pishchyk"
Br J Clin Pharmacol
November 2024
Article Synopsis
- Dostarlimab-gxly is a monoclonal antibody targeting the PD-1 receptor, and the RUBY study aimed to analyze its pharmacokinetics and efficacy in patients with advanced endometrial cancer.
- The study combined data from the RUBY and GARNET trials, examining the safety and efficacy of dostarlimab through regression analyses.
- Results indicated that combining dostarlimab with standard care had a minimal impact on its pharmacokinetics, with no significant adverse effects or relationships affecting patient outcomes.
